KRAS and neoplasm: Following this treatment, KRAS(wt) clone showed a tumor weight reduction between treated and control groups reaching statistical significance on days 39, 42 and 45 (p < 0.0001) after tumor implant with a best treated over control ratio (T/C) of 36% at day 45 (Figure 2b).